No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MRK Merck & Co
- 125.540
- +1.010+0.81%
Close May 31 16:00 ET
- 126.000
- +0.460+0.37%
Post 19:33 ET
317.97BMarket Cap139.49P/E (TTM)
126.610High124.550Low18.15MVolume125.130Open124.530Pre Close2.28BTurnover0.72%Turnover Ratio896.71P/E (Static)2.53BShares133.10052wk High7.88P/B317.18BFloat Cap97.80652wk Low3.00Dividend TTM2.53BShs Float133.100Historical High2.39%Div YieldTTM1.65%Amplitude18.229Historical Low125.516Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
FDA Oncology Chief Says International Clinical Trials Should Be Priority
Summit Lead Asset Approved in China for Lung Cancer
Merck (NYSE:MRK) Seems To Use Debt Quite Sensibly
Immunocore Touts Updated Phase 1 Results for Melanoma Asset Brenetafusp
Express News | NYSE Order Imbalance 736495.0 Shares on Buy Side
Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company's stock closed 272.1% higher at $10.92 on Thursday.Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced
Comments
$Merck & Co(MRK.US$
⇨ $1.3B upfront payment & up to $1.7B in future milestone payments 💰
⇨ Includes Restoret™, novel late-phase candidate 👁️
» for diabetic macular edema and neovascular age-related macular degeneration
» enter pivotal study for DME in H2 2024
⇨ Deal to close in Q3 2024
⇨ $1.3B upfront payment & up to $1.7B in future milestone payments 💰
⇨ Includes Restoret™, novel late-phase candidate 👁️
» for diabetic macular edema and neovascular age-related macular degeneration
» enter pivotal study for DME in H2 2024
⇨ Deal to close in Q3 2024
7
Morning Movers
Gapping up
$Marathon Oil(MRO.US$ stock rose more than 7% following the announcement of being acquired by ConocoPhillips in a $17.1 billion all-stock deal.
$NVIDIA(NVDA.US$ stock rose 0.4%, continuing to climb after the tech giant's hefty 7% gains the previous session.
$Dick's Sporting Goods(DKS.US$ popped 7.7% after reporting an earnings and revenue beat for its fiscal first quarter and raising its full year gui...
Gapping up
$Marathon Oil(MRO.US$ stock rose more than 7% following the announcement of being acquired by ConocoPhillips in a $17.1 billion all-stock deal.
$NVIDIA(NVDA.US$ stock rose 0.4%, continuing to climb after the tech giant's hefty 7% gains the previous session.
$Dick's Sporting Goods(DKS.US$ popped 7.7% after reporting an earnings and revenue beat for its fiscal first quarter and raising its full year gui...
25
$Esperion Therapeutics(ESPR.US$ Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, have positioned it as defininte acquistion target for larger pharmaceutical companies. Esperion's drugs NEXLIZET and NEXLETOL now have primary prevention labels, NEXLIZET will soon become the drug of choice over a PCSK9 inhibitor says Texas based HeartPlace leading Cardio...
12
Interesting both for the (1) shift in the macro-trend to M&A (vs. Licensing) and (2) change in top spenders
$Merck & Co(MRK.US$ $Bristol-Myers Squibb(BMY.US$ $Johnson & Johnson(JNJ.US$ $Pfizer(PFE.US$ $Novo-Nordisk A/S(NVO.US$ $AbbVie(ABBV.US$
$Merck & Co(MRK.US$ $Bristol-Myers Squibb(BMY.US$ $Johnson & Johnson(JNJ.US$ $Pfizer(PFE.US$ $Novo-Nordisk A/S(NVO.US$ $AbbVie(ABBV.US$
10
1
See remaining FDA PDUFAs in May 👀👇
$Bristol-Myers Squibb(BMY.US$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna(MRNA.US$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals(CPRX.US$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline(GSK.US$ : Arexvy
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : Elafibranor
$Regeneron Pharmaceuticals(REGN.US$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US$ : Augtyro...
$Bristol-Myers Squibb(BMY.US$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna(MRNA.US$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals(CPRX.US$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline(GSK.US$ : Arexvy
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : Elafibranor
$Regeneron Pharmaceuticals(REGN.US$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US$ : Augtyro...
7
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
